“国17条”政策下临床药学的发展战略 [Abstract] In 2017, the General Office of the State Council promulgated the“Opinions of the General Office of the State Council on Further Reforming and Perfecting the Policy on the Use of Drug Production and Circulation”, referred as "State 17 articles" in the industry. The document is not only a development opportunity,but also a serious challenge for clinical pharmacy and hospital pharmacy. Based on this, the author summed up the understanding of the document from a number of industry leaders and experts, and understood its deep interpretation, to provide reform ideas and development strategies for relevant units of the pharmaceutical sector . 2017年2月9日,务院办公厅发布了《国务院办公厅关于进一步改革完善药品生产流通使用政策的若干意见》[1][国办发〔2017〕13号],业内简称“国17条”。该文件从提高药品质量疗效,促进医药产业结构调整;整顿药品流通秩序,推进药品流通体制改革;规范医疗和用药行为,改革调整利益驱动机制等三个层次为药品的生产、流通及使用提供了指导方针及发展方向。这既是临床药学及医院药学的发展机遇,同时也是严峻的挑战。为此,本文主要总结多位业内领导、专家对该文件的认识及理解,对其进行了深层次的解读,以期为各相关单位的药学部门提供改革思路及发展战略。1 改革方向